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ABSTRACT
A new dipeptide, (-)-glaciantarcin (1) and three known compounds, cyclo(-Pro-Gly) (2), 1-(2-deoxypentofuranosyl)-5-
methyl-2,4(1H,3H)-pyrimidinedione (3) and vidarabine (Ara-A) (4), were isolated from Glaciozyma antarctica PI12, 
a cold-adapted yeast. The chemical structures were elucidated by FT-IR, NMR and mass spectrometry. The cytotoxicity 
and antioxidant activities of compounds 1-4 were evaluated by using the MTT bioassay on MCF-7 (human breast cancer 
cell line), PC-3 (human prostate cancer cell line) and HEK-293 (normal human embryonic kidney cell line) and DPPH 
free radical scavenging activity, respectively. At concentration of 400 µM, all compounds showed the highest activity 
on MCF-7, with compound 1 at 65%, compound 2 (70%), compound 3 (66%) and compound 4 (58%) cell viability. All 
compounds exhibited weak antioxidant properties. To the best of our knowledge, this is the first report of compounds 
1-4 from Glaciozyma antactica.
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ABSTRAK
Satu dipeptida terbaharu iaitu  ((-)-glasiantarsin (1) dan tiga sebatian yang telah diketahui; siklo (-Pro-Gli) (2), 1- 
(2-Deoksipentofuranosil) -5-metil-2,4 (1H, 3H) -pirimidinedion (3) dan vidarabin (Ara-A) (4) telah diasingkan daripada 
Glaciozyma antarctica PI12, yis yang teradaptasi sejuk. Struktur kimia dijelaskan oleh spektroskopi inframerah (IM), 
ultra lembayung (UL), resonans magnetik nuklear (RMN) dan spektroskopi jisim. Aktiviti  kesitotoksikan dan antioksidan 
daripada sebatian 1-4 dinilai menggunakan bioasai MTT ke atas MCF-7 (sel kanser payudara manusia), PC-3 (sel kanser 
prostat manusia) dan sel HEK-293 (sel normal) serta aktiviti perencatan radikal bebas DPPH. Pada kepekatan 400 
μM, semua sebatian menunjukkan aktiviti tertinggi ke atas MCF-7, iaitu masing-masing: sebatian 1 (62 ± 0.9), 2 (66 ± 
1.6), 3 (62 ± 1.3) dan 4 (55 ± 1.7). Kesemua sebatian terpencil menunjukkan sifat antioksidan yang lemah. Sepanjang 
pengetahuan kami, ini merupakan laporan pertama sebatian 1-4 daripada Glaciozyma antactica.     
Kata kunci: Aktiviti biologi; dipeptida;  ((-)-glasiantarsin;  Glaciozyma antarctica PI12; yis psikrofilik
INTRODUCTION
Since the 1960s, bioactive secondary metabolites were 
isolated and structurally characterised from microorganisms 
which have adopted strategies to grow in extreme terrestrial 
environments (Lesley-Ann & David 2015). Glaciozyma 
antarctica PI12 belongs to the family Kriegeriales (Di 
Menna 1960) and was isolated from a marine environment 
in Antarctica (Fell et al. 1969). Recently, this psychrophilic 
yeast was reclassified from Leucosporidium antarcticum 
to Glaciozyma antarctica PI12 (Turchetti et al. 2011) and 
was also isolated from various locations in Antarctica 
(Connell et al. 2008; Donachie 1995). Turkiewicz et al. 
(2005) reported that G. antarctica PI12 has optimum 
growth temperature of around 15°C and is able to tolerate 
higher temperatures up to 20°C (Morita 1975). 
 This paper reports the isolation and elucidation of 
secondary metabolites from G. antarctica PI12 fermented 
at 12°C with complete nutrient (optimised growth 
conditions). A new dipeptide, (-)glaciantarcin (1) and 
three known compounds, cyclo(-Pro,Gly) (2) (Ishizu et 
al. 1991), 1-(2-deoxypentofuranosyl)-5-methyl-2,4(1H,3H)-
pyrimidinedione (Setyowati et al. 2008) and vidarabine 
(Ara-A) (4) (Lagoja 2005), were isolated from the ethyl 
acetate extract of G. antarctica PI12 and their structures 
were established by Nuclear Magnetic Resonance 
Spectroscopy and Mass Spectrometry techniques. 
The antioxidant properties and cytotoxicity activity of 
compounds 1-4 against two cancer cell lines, MCF-7 and 
PC-3 and the normal cell line HEK 293 are also included.
MATERIALS AND METHODS
GENERAL
Silica gel; Kieselgel 60 PF254 (art. no. 7749, Merck) and 
aluminum sheets 20 × 20 cm of the silica gel 60 F254 
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of 0.25 mm thickness (art. no. 5554, MERCK) were used 
for radial and thin layer chromatography, respectively. 
Structures of the pure compounds were determined 
based on the spectral data recorded on Shimadzu UV-260 
spectrophotometer, optical rotation (Rudolph research 
analytical, Autopol VI), Jasco J-815 CD spectrometer, 
Frontier Perkin-Elmer FTIR/NIR spectrophotometer and 
Bruker NMR 700 MHz cryo-probe instrument that included 
1-D and 2-D NMR. ESI-MS were recorded by using LCMS-
Ultra performance liquid chromatography (UPLC), Brand 
WATER. 
BIOLOGICAL MATERIAL AND CULTIVATION OF YEAST
The G. antarctica PI12 was originally isolated from Casey 
Research Station, in Antarctica. This yeast was identified 
based on its biochemical characteristics and the sequence 
of the internal transcribed spacer (ITS) as well as the LSU 
rRNA (Accession numbers JX89896955 and JX896956) 
by the National Collection of Yeast Cultures, Norwich, 
UK. The strain was cultured on Tryptic Soy Agar for 10 
days at 4°C until a single colony was obtained (Hashim et 
al. 2014). Firstly, 10 μL of the G. antarctica PI12 glycerol 
stock was sub-cultured on the YPD agar with 50 μg/mL 
of ampicillin and 50 μg/mL kanamycin at 12°C until a 
single colony was obtained.  Secondly, a starter culture of 
G. antarctica PI12 was prepared by inoculating a single 
colony of G. antarctica PI12 from the agar plate into 10 
mL of YPD medium (50 mL falcon tube) with 50 μg/mL of 
ampicillin and 50 μg/mL kanamycin. Then it was cultured 
at 12°C at 180 rpm until mid-log phase (OD600: 1.0 to 1.8) 
(5 days). Thirdly, a fixed amount (106 yeast cells/mL) of 
starter culture was inoculated into 50 mL of YPD medium 
(three units of 250 mL conical flask were used) with two 
antibiotics and then cultured at 12°C at 180 rpm until 
stationary phase on day 14 (Hashim et al. 2013).
EXTRACTION AND ISOLATION
The fermented culture was centrifuged at 10,000 rpm, 
4°C, for 5 min. The supernatant was filtered to remove 
cell debris and extracted thrice with ethyl acetate, to be 
concentrated under reduce pressure evaporator. The EtOAc 
extract (200.7 mg) of G. antarctica PI12 was subjected to 
radial chromatography (RC) with 1 mm thickness silica gel 
on a round glass plate and eluted with mixtures of DCM and 
MeOH with increasing polarity (initially DCM/MeOH, 9.6 
: 0.4). Eluents that showed the same profile on thin layer 
chromatography (TLC) chromatogram were combined to 
give three fractions (I-III). Purification of fraction I (1-4) 
(29.7 mg) was carried out by using RC with a silica gel 
plate of 0.5 mm thickness eluted with DCM and MeOH 
(9.2:0.8) in 5% polarity increment to yield compound 
1 (4 mg). Purification of fraction II (5-7) (48.8 mg) was 
conducted by utilising another RC with silica gel plate of 
0.5 mm thickness. Elution with DCM and MeOH (8.4:1.6) 
provided compound 2 (2 mg), compound 3 (1.5 mg) and 
compound 4 (7.5 mg).  
CYTOTOXICITY ASSAY
Compounds 1-4 were subjected to anticancer screening 
by using breast adenocarcinoma cells (MCF-7) and human 
prostate cancer cells (PC-3). Toxicity assessment of the 
compounds was conducted by using human embryonic 
kidney normal cell line (HEK-293). All cell lines were 
grown in a suitable media and maintained in a humidified 
atmosphere of 95% air and 5% CO2 at 37°C. For the 
assay, cells were detached, centrifuged and the viability 
of the cells was determined by Trypan blue dye exclusion 
technique. The cell suspension was diluted to give the 
optimal cell seeding density. Cytotoxic analysis of the 
cells was determined by using iCELLigence impedance-
based, time-dependent cellular response profiles (TCRPs) 
system and further confirmed by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
The anticancer drug, doxorubicin was used as a positive 
control.
 C e l l  v i a b i l i t y  w a s  a s s e s s e d  b y  u s i n g 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay, which was based on the reduction 
of MTT by mitochondrial dehydrogenases of viable cells 
to a purple formazan product. Firstly, cells were plated 
at 2.5 × 104 cells/mL of density in 96-well plate. After an 
overnight growth, the cells were treated with Compounds 
1-4, with concentrations ranging from 12.5 to 400 μM for 
48 h. Next, the cells were incubated with 10 μL of 4 mg/
mL MTT dye at 37°C for 3 h. After the media was removed 
from the plate, 100 μL of DMSO was added, followed by 
absorbance measurement at 570 nm by using a microplate 
reader (Mosmann 1983).
ANTIOXIDANT (DPPH)
The stock concentration of each compound was 1 mg/mL 
in MeOH. For bioassay, 50 μL of each sample was added 
to 150 μL of 0.3 mM solution of DPPH. The mixture was 
vigorously shaken and allowed to stand in a dark place 
for 30 min; the absorbance at 517 nm was determined by 
using a UV spectrophotometer and the scavenging activity 
percentage was calculated. A blank solution of MeOH 
was prepared. BHT (butylated hydroxy toluene) and BHA 
(butylated hydroxy anisole) were used as positive controls 
(Brand-Williams et al. 1995). 
(-)-GLACIANTARCIN (1)
White solid; -102.07 (c 0.10, MeOH); m.p 186-187°C; IR 
(ATR): 3044-2881, 1660, 1326, 1454, 1094, 886-758 cm-
1; ESI-MS: [M + H+] m/z 170.2350 (calcd. for C7H12N3O2: 
170.1220); 1H NMR (MeOD, 700 MHz) and 13C(APT) NMR 
(175 MHz): Table 1.
CYCLO(-PRO-GLY) (2)
Clear needle crystal; m.p 222-223°C; IR (ATR): 3191, 1640, 
1453, 1332, 1294-1217, 1110, 1004, 922-764 cm-1; ESI-MS: 
[M + H+] m/z 155.1750 (calcd. for C7H11N2O2: 155.0821); 
1H NMR (MeOD, 700 MHz): δH 4.13 (Ψd, 1H, H-3), 3.77 
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(d, 1H, H-3), 8,13 (br-s, 1H, 4-NH), 4.25 (Ψt, J = 7 Hz, 
1H, H-6), 2.34 (t, J = 7 Hz, 1H, H-7), 1.99 (t, J = 7 Hz, 1H, 
H-7), 2.04 (m, 1H, H-8), 1.95 (m, 1H, H-8), 3.57 (Ψt, J = 
7 Hz, 1H, H-9), 3.54 (Ψt, J = 7 Hz, 1H, H-9); 13C(APT) 
NMR (MeOD, 175 MHz): δC 165.1 (Cq-2), 45.6 (CH2-3), 
170.6 (Cq-2), 58.4 (CH-6), 27.9 (CH2-7), 21.9 (CH2-8), 
44.9 (CH2-9).
1-(2-DEOXYPENTOFURANOSYL)-5-METHYL-2,4(1H,3H)-
PYRIMIDINEDIONE (3)
White solid; UV active; m.p 355-356°C; IR (ATR): 3500-
3200, 2931-2839, 1678, 1421, 1272, 1029 cm-1; ESI-MS: 
[M + H+] m/z 243.2240 (calcd. for C10H15N2O5: 243.0981); 
1H NMR (MeOD, 700 MHz): δH 7.83 (s, 1H, H-6), 1.90 
(s, 3H, H-7), 6.29 (t, J = 7 Hz, 1H, H-2`), 2.24  (m, 2H, 
H-3`), 4.41 (m, 1H, H-4`), 3.92 (q, J = 3.36 Hz, 1H, H-5`), 
3.81 (dd, J1 = 3.22, J2 = 12.04 Hz, 1H, H-6`), 3.78 (dd, J1 
= 3.64, J2 = 12.04 Hz, 1H, H-6`); 13C(APT) NMR (MeOD, 
175 MHz): δC 151.1 (Cq-2), 165.0 (Cq-4), 110.3 (CH-5), 
136.8 (Cq-6), 11.0 (CH3-7), 84.8 (CH-2`), 39.8 (CH2-3`), 
70.8 (CH-4`), 87.4 (CH-5`), 61.4 (CH2-6`).
VIDARABINE (ARA-A) (4)
White solid; UV active; IR (ATR): 3400, 3300, 3134-2879, 
1604-1420, 1577, 1100-1028 cm-1; ESI-MS: [M + H+] m/z 
268.3350 (calcd. for C10H14N5O4: 268.10471H NMR (MeOD, 
700 MHz): δH 8.20 (s, 1H, H-2), 8.33 (s, 1H, H-8), 5.97 (d, 
J = 7 Hz, 1H, H-2`), 4.34 (dd, J1 = 7, J2= 14 H , 1H, H-3`), 
4.75 (t, J = 7 Hz, 1H, H-4`), 4.18 (q, J = 7 Hz, 1H, H-5`), 
3.91 (dd, J1 = 7, J2 = 14 Hz, 1H, H-6`), 3.76 (dd, J1 = 7, J2 
= 14 Hz, 1H, H-6`); 13C(APT) NMR (MeOD, 175 MHz): 
δC 152.1 (Cq-2), 148.6 (Cq-4), 119.6 (Cq-5), 156.2 (Cq-6), 
140.6 (Cq-8), 89.8 (CH-2`), 71.3 (CH-3`), 74.0 (CH-4`), 
86.8 (CH-5`), 62.1 (CH2-6`).
RESULTS AND DISCUSSION
A new compound, (-)-glaciantarcin (1) was isolated 
as white amorphous solid (Figure 1). The molecular 
formula is C7H11N3O2, generated using MS [M + H+] at 
m/z 170.1034 (calc. for C7H12N3O2 170.1220). Compound 
1 was suggested to have a carbonyl group linked with the 
secondary and tertiary amide (1660 cm-1) based on its IR. In 
addition, the IR spectra also showed a weak band presence 
for a primary amine (885-758 cm-1) and secondary amine 
(1326 cm-1), which supported by signals from 1H-NMR at 
δH 4.60 (2H, br-s, 8-NH2) and 8.02 (1H, br-s, 1-NH) ppm, 
respectively (Table 1). The 1H-NMR showed signals of a 
methyl group at δH 1.45 (3H, d, J = 7.0 Hz, H-9) adjacent 
to methine group at δH 4.03 (1H, q, J1 = 7.0, J2 = 14.0 
Hz, H-8). The olefinic protons were confirmed by signals 
at δH 5.63 (1H, d, J = 7.0 Hz, H-6) and 7.41 (1H, d, J = 
7.0 Hz, H-7). The presence of two carbonyl groups was 
confirmed by 13C-NMR at signals δc 170.2 (C-5) and 167.4 
(C-2). Two signals of methines at δc 100.9 (C-6) and 142.0 
(C-7) indicated the presence of an olefinic carbon, that is 
linked to a quaternary carbon C-5, while the other three 
shielded carbons (C-3, C-8, and C-9) showed the existence 
of an aliphatic amide in the molecule. The DBE value of 
C7H11N3O2 is four, indicating that the alkaloid consists of 
three double bonds (one olefinic and two carbonyls) and 
one ring of diazepine derivative.
 The structure of Compound 1 was confirmed by using 
2D NMR, including HMBC and H1/H1 COSY. The HMBC 
experiment showed that H-8 has correlations with carbonyl 
C-5 and methylene C-3, confirming the position of the 
4-(1-aminoethyl) as a branch in this molecule (Figure 2).
 Most probably Compound 1 was derived from the 
nonribosomal peptide synthetase (bimodular NRPS) 
pathway. The proposed mechanism was by using β-amino 
acid (3-amino-3-hydroxy propanoic acid) as the starter 
FIGURE 1. Compounds isolated from G. antarctica PI12
FIGURE 2. 2D Correlation NMR of (-)-glaciantarcin (1); HMBC (→), COSY (––)
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unit with glycine as extender (Figure 3). The utilisation 
of β-amino acid as a starter was well established in 
the microbial metabolites (Kudo et al. 2014). These 
substrates were tethered to the thiolation domains of 
the NRPS and underwent condensation reaction. Next, 
subsequent cyclisation and dehydration took place for 
the formation of the seven-membered diazepine ring 13. 
Further modifications were needed for the production of 
Compound 1. 
 Further purification with radial chromatography 
afforded another dipeptide (Compound 2) ,  and 
pyrimidine derivatives Compound 3 and Compound 4. 
All these compounds were known, and were isolated 
from microbial sources. Compounds 2-4 were identified: 
Compound 2 was cyclo(Pro-Gly), Compound 3 was 
1-(2-deoxypentofuranosyl)-5-methyl-2,4(1H,3H)-
pyrimidinedione, and Compound 4 was vidarabine (Ara-A) 
by comparison of their NMR and MS data with the reported 
values in literature. This is the first report on Compounds 
1-4 from G. antarctica PI12 (Figure 1).
 Compound 2 was reported to be first isolated from 
fungi Aspergillus fumigatus, with antimicrobial activities 
(Furtado et al. 2005). The pyrimidine derivative Compound 
3 was originally isolated from sponge, with in vitro 
cytotoxicity (HeLa, Raji and myolema cells) bioactivities 
(Setyowati et al. 2008). Compound 4 was originally 
developed as a synthetic analogue from spongouridine, 
a compound isolated from the Caribbean sponge Tethya 
crypta (Tethylidae) with good antiviral activity (Bergmann 
et al. 1951). However, Compound 4 was isolated from 
TABLE 1. NMR data of (-)-glaciantarcin (1)
Position 1
δH (m, J in Hz) δC
1-NH 4.60 (br-s) -
2 - 167.4
3 3.94 (2H, d, J = 7.0 Hz) 44.0
5 - 170.2
6 5.63 (d, J = 7.0 Hz) 100.3
7 7.41 (d, J = 7.0 Hz) 142.1
8 4.03 (q, J1 = 7.0, J2 = 14.0 Hz) 50.3
8-NH2 8.02 (br-s) -
9 1.45 (d, J = 7.0 Hz) 18.0
*HMBC correlations are from hydrogen(s) stated to the indicated carbon for 3-bond and 2-bond couplings
FIGURE 3. Proposed Biosynthesis of (-)-glaciantarcin (1)
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sponge Haliclona sp., proving that this compound can also 
be synthesised by a biological system (Wang et al. 2009).
All of the isolated Compounds (1-4) were assayed for 
cytotoxicity against human breast cancer (MCF-7) and 
human prostate cancer (PC-3) cell lines. Their toxicity 
towards normal cells was also tested by using a normal 
human embryonic kidney (HEK-293) cell line. At the 
highest concentration of 400 μM, all compounds showed 
the best activity on MCF-7, with Compound 1 (65%), 
Compound 2 (70%), Compound 3 (66%) and Compound 
4 (58%) cell viability. A lower concentration of all 
compounds gave more than 70% cell viability.
 The DPPH radical scavenging activity of the compounds 
showed weak antioxidant activities at a fixed concentration 
of 100 μM; with Compounds 1-4 at 7.49%, 24.83%, 
11.56%, and 4.15%, respectively. 
CONCLUSION
The investigation on the chemical constituents from EtOAc 
extract of psychrophilic yeast Glaciozyma antarctica 
PI12 resulted in the isolation of a new compound namely 
(-)-glaciantarcin (1) and three known compounds which 
were cyclo(-Pro-Gly) (2), 1-(2-deoxypentofuranosyl)-5-
methyl-2,4(1H,3H)-pyrimidinedione (3) and vidarabine 
(Ara-A) (4). In cytotoxicity bioassay, at the concentration 
of 400 μM, all compounds showed the highest activity on 
MCF-7, with Compounds 1-4 at 65%, 70%, 66% and 58% 
cell viability, respectively. All compounds showed weak 
DPPH radical scavenging activity. This study shows that 
Glaciozyma antarctica mainly produces nitrogen-based 
compounds when grown in optimised conditions.
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